Vascularized pancreatic islet-on-chip for type 1 diabetes - France Génomique Access content directly
Conference Papers Year : 2024

Vascularized pancreatic islet-on-chip for type 1 diabetes


Diabetes is a growing threat to global health, currently affecting 537 million people worldwide, or 1 in 10 adults. The World Health Organization predicts that 783 million people will suffer from diabetes in 2045. Diabetes, type 1 or 2, cause an abnormal and prolonged increase of the blood glucose level, mainly caused by deficiency or failure to use insulin. In the long term, diabetes can lead to many complications, including vasculopathy, neuropathy, retinopathy, and diabetic foot ulcer. There is a need to understand the mechanisms of action in a human model in order to finely-tune the treatment for each patient. Building in vitro analytical tools is crucial to model the complexity of physiology and pathophysiology of pancreatic islets for a better understanding of its basic biology as well as for the screening of new drugs. While most common perifusion systems require pooling of multiple islets to achieve quantifiable insulin concentrations, minimizing the number of islets required for experiments using microfluidic platforms is important given the scarcity of these biological tissues.
Fichier principal
Vignette du fichier
EUROoCS_2024_Abstract_48 (1).pdf (40.05 Ko) Télécharger le fichier
Origin : Files produced by the author(s)

Dates and versions

hal-04399755 , version 1 (17-01-2024)


  • HAL Id : hal-04399755 , version 1


Emily Tubbs, Clément Quintard, Amandine Pitaval, Joris Kaal, François Boizot, et al.. Vascularized pancreatic islet-on-chip for type 1 diabetes. EUROocs 2024 - EUROoCS Annual Meeting 2024, Jul 2024, Milan, Italy. ⟨hal-04399755⟩
53 View
34 Download


Gmail Facebook X LinkedIn More